Arsenal Capital Partners Announces Sale Of Scientific Protein Laboratories, Inc.
Published: Aug 18, 2006
NEW YORK, Aug. 18 /PRNewswire/ -- Arsenal Capital Partners , an industry- focused investor in lower-middle market, niche manufacturing and service companies, today announced the sale of its portfolio company Scientific Protein Laboratories LLC and affiliated entities (together "SPL") to American Capital Strategies Ltd. . SPL is a leading global independent manufacturer and supplier of biologic active pharmaceutical ingredients (APIs), including heparin and pancreatin APIs. Arsenal initially acquired SPL in February 2004 from Wyeth. Terms of the transaction were not disclosed.
"With investments in niche healthcare companies like SPL, Priority Solutions, and Leis Medical, Arsenal is taking advantage of strong growth trends in the outsourced pharmaceutical and medical technology markets. We are actively pursuing new investments in these sectors," said James Marden, a Managing Director of Arsenal Capital Partners.
"We appreciate the efforts of Arsenal Capital Partners in helping SPL transition to a standalone company and position the company for its next stage of growth," said Scientific Protein Laboratories CEO David Strunce.
Banc of America Securities LLC acted as financial advisor to SPL in the transaction.
About Arsenal Capital Partners
Arsenal Capital Partners invests in specialty product and services companies in industries where it has substantial prior experience and expertise and can support management teams to drive growth and improve productivity. Arsenal focuses on growing, niche markets including healthcare, specialty chemicals, aerospace/defense, specialty components and distribution/logistics. For additional information please visit www.arsenalcapital.com.Arsenal Capital Partners
CONTACT: Christopher Tofalli, +1-914-834-4334
Web site: http://www.arsenalcapital.com/